Can ajovy be given once every three months?

What is the dosing regimen for AJOVY?

AJOVY (fremanezumab-vfrm) is a humanized monoclonal antibody that is used for the prevention of migraine in adults. According to the prescribing information, the recommended dosing regimen for AJOVY is a fixed 225 mg dose administered subcutaneously once a month [1].

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/209819s000lbl.pdf [Label] - Source: AJOVY official prescribing information.

Can AJOVY be given less frequently?

The efficacy and safety of AJOVY given every three months have not been established, and it may not be effective at this dosing frequency. AJOVY is a medication that is designed to provide continuous protection against migraine attacks, and the once-monthly dosing schedule is intended to maintain therapeutic levels of the drug in the body.

Impact of reduced dosing frequency on AJOVY efficacy

Giving AJOVY every three months may lead to a decrease in the drug's efficacy in preventing migraine attacks. Studies have shown that the peak concentrations of fremanezumab in the body are reached within 7-10 days after administration, and these concentrations decline over time. By extending the dosing interval to every three months, the peak concentrations may not be sufficiently maintained, resulting in reduced efficacy against migraine attacks.

Regulatory perspective

Labeling and guidance statements from regulatory agencies such as the US Food and Drug Administration (FDA) reflect the approved dosing regimen for AJOVY. According to FDA labeling, "the efficacy and safety of AJOVY for the prevention of migraine attacks have not been established at a dose interval greater than every 4 weeks" [2].

[2] https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-fda-approval-status [Approved Drugs Database] - Source: AJOVY approval status at FDA.

Practical implications for healthcare providers and patients

Given the lack of evidence supporting the efficacy of AJOVY given every three months, healthcare providers should counsel patients on the importance of adhering to the recommended dosing regimen to maximize the benefits of the medication. Patients should discuss any concerns or doubts they have with their healthcare provider to determine the best treatment strategy for their individual needs.

Conclusion

Based on the available evidence, AJOVY should not be given every three months. The approved dosing regimen for AJOVY is once a month, and this schedule is intended to maintain the drug's efficacy in preventing migraine attacks. Patients and healthcare providers should work together to determine the best treatment strategy for migraine prevention.

Sources

1. https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/209819s000lbl.pdf [AJOVY Prescribing Information]
2. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-fda-approval-status [FDA Approved Drugs Database]